Sandostatin® LAR® Delivers Powerful Efficacy and Unparalleled Evidence

Home > Treating Acromegaly  > Treatment and Management of Acromegaly > Dosing of Sandostatin LAR

Dosing of Sandostatin® LAR® for Acromegaly

Patients Currently Receiving Sandostatin®1

Patients who are currently receiving the standard formulation of Sandostatin can be switched directly to the slow-release depot formulation, Sandostatin LAR, using a dosage of 20 mg administered intragluteally at 4-week intervals for the initial
3 months. Dosage may need to be increased up to 30 mg if symptoms and biochemical control are not achieved during follow-ups.

Patients Currently Not Receiving Sandostatin1

In patients who are not currently receiving Sandostatin, the standard injection formulation should be given subcutaneously at an initial dose of 50 µg 3 times a day. Dosage titration can be based on multiple GH measurements at 0 to 8 hours after administration.

  • Most patients require a dosage of 100 µg to 200 µg 3 times a day for the maximum effect of normalising GH and IGF-1
  • Some patients may require up to 500 µg 3 times a day

Patients should be maintained on this formulation for at least 2 weeks to determine their response and tolerability to Sandostatin.

Patients who tolerate the drug and are considered to be responders to the therapy based on GH and IGF-1 levels can be switched to Sandostatin LAR. The dosage should be 20 mg administered intragluteally at 4-week intervals for the initial 3 months. Dosage may need to be increased up to 30 mg if symptoms and biochemical control are not achieved during follow-ups.

Click here for information on preparation and administration of Sandostatin.

Reference: 1. Sandostatin® LAR® Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.


sandostatin.com